Posted by Michael Wonder on 01 Mar 2023
Janssen submits new drug application to the US FDA seeking approval of niraparib and abiraterone acetate dual action tablet, plus prednisone, as a first-line targeted treatment for patients with metastatic castration-resistant prostate cancer with BRCA gene mutations
28 February 2023 - Niraparib and abiraterone acetate plus prednisone has potential to address unmet need for patients with BRCA positive metastatic castration-resistant prostate cancer.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a new drug application to the US FDA seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual action tablet, plus prednisone, for the treatment of patients with BRCA positive metastatic castration-resistant prostate cancer.
